Retatrutide’s TRIUMPH-1 and semaglutide’s STEP 1 both used placebo comparators. They enrolled different study populations and assessed weight change at different times.
Compare study designs before outcomes
The respective headline results can be reported side by side as a study comparison. An obesity-specific superiority claim requires a direct comparison in the same population with a common outcome definition.
| Intervention | Trial | Follow-up | Mean weight reduction | Context |
|---|---|---|---|---|
| Retatrutide | TRIUMPH-1 | 80 weeks | 28.3% vs 2.2% placebo | Sponsor efficacy analysis; 12 mg arm |
| Tirzepatide | SURMOUNT-1 | 72 weeks | 20.9% vs 3.1% placebo | 15 mg arm |
| Semaglutide | STEP 1 | 68 weeks | 14.9% vs 2.4% placebo | 2.4 mg arm |
These percentages come from separate trials. Their populations, study durations, analysis methods and placebo responses differ. In SURMOUNT-5, the direct tirzepatide and semaglutide comparison yielded 20.2% and 13.7% mean reductions, respectively, at 72 weeks.
How to interpret the evidence
Keep the indication and formulation clear when reading any comparison involving semaglutide. Diabetes studies answer different questions from obesity studies.
Give the strongest weight to studies that randomized both treatments within a shared protocol for the clinical question you are asking.